Please login to the form below

Not currently logged in
Email:
Password:

Promacta

This page shows the latest Promacta news and features for those working in and with pharma, biotech and healthcare.

Alcon spun off, leaner Novartis raises profit forecast

Alcon spun off, leaner Novartis raises profit forecast

treatments Lutathera ($106m), Promacta ($307m), Kisqali ($91m) and Kymriah ($45m).

Latest news

  • FDA clears Dova drug for liver-related low blood platelets FDA clears Dova drug for liver-related low blood platelets

    Drug is in the same class as Novartis’ Promacta/Revolade. Dova Pharmaceuticals has won its first product approval, getting a green light from the FDA for Doptelet as a treatment for ... Doptelet is in the same class as Novartis’ Promacta/Revolade

  • Novartis’ Promacta receives US breakthrough therapy designation Novartis’ Promacta receives US breakthrough therapy designation

    We will continue to work closely with the FDA to make Promacta available to patients with SAA who are new to treatment as soon as possible.”. ... Regulatory filings for a first-line indication in the US and Europe are expected to be made for

  • Novartis bags EU approvals for three ex-GSK drugs Novartis bags EU approvals for three ex-GSK drugs

    Revolade - sold as Promacta in the US - has previously been approved to treat the rare disorder chronic immune thrombocytopenia (ITP) in Europe and is also authorised for both ITP and SAA ... Promacta is one of the products from the GSK transaction that

  • Novartis aims to lead immuno-oncology category Novartis aims to lead immuno-oncology category

    The recent acquisition of cancer drugs from GlaxoSmithKline - which included Votrient (pazopanib), Tafinlar (dabrafenib), Mekinist (trametinib) and Promacta (eltrombopag) - added to its portfolio of targeted cancer therapies that can be combined

  • Novartis gets FDA nod for rare blood disorder drug Novartis gets FDA nod for rare blood disorder drug

    The FDA has approved Novartis' Promacta for the treatment of children over six with chronic immune thrombocytopenia (ITP), seven years after it was given the nod for adults. ... Promacta (eltrombopag) will be a treatment option for child patients who

More from news
Approximately 5 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). GSK will continue with its immunotherapy and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics